We apologize for any inconveniences as the site is being expanded with new modules & functionalities being added.

Source: Singapore Medical News  Jun 23, 2020  21 days ago
WARNING! Singapore Medical News: New Serotype Of Dengue Virus In Singapore Hides Itself To Evade Recovery
WARNING! Singapore Medical News: New Serotype Of Dengue Virus In Singapore Hides Itself To Evade Recovery
Source: Singapore Medical News  Jun 23, 2020  21 days ago
Singapore Medical News: Disturbingly, Singapore saw 1,377 dengue cases in the week ending 20th of June, the highest number of weekly dengue cases ever recorded since 2014.

Significantly, the dengue virus serotype 3 (DENV3), which is currently circulating in Singapore, can undergo dramatic structural changes that enable it to resist vaccines and drugs, according to findings from a research by scientists from Duke-NUS Medical School.
The research findings were published in the journal: Nature Communications. https://www.nature.com/articles/s41467-020-16925-y
The study findings could guide the development of effective vaccines and therapeutics against the dengue infection.
Disturbingly, dengue infections are rising, even as public health authorities are battling to contain the spread of the coronavirus. Dengue virus serotype 2 (DENV2) had previously been the predominant serotype but DENV3 has re-emerged in Singapore after almost three decades. This means the Singapore population has lower immunity to DENV3 and, consequently, a large proportion of the population is susceptible to DENV3 infection.
To date, there are no highly protective vaccines or therapeutic agents that target DENV. This is due to the possibility that antibodies raised against any one of the four known serotypes (DENV1-4) may enhance disease severity when an individual is infected with a different serotype in a secondary infection.
This implies that an effective vaccine has to be able to stimulate equally strong protective responses simultaneously against all four serotypes. Adding further complication to vaccine development is the fact that there are different virus strains within each serotype, and different strains can exhibit vastly different shapes, enabling them to escape detection by a host's immune system.
The researchers from Duke-NUS had previously discovered that the surface of the DENV2 can change from smooth to bumpy depending on host conditions.
Professor Dr Sheemei Lok from the Duke-NUS' Emerging Infectious Diseases (EID) program and corresponding author of this study told media, "Past structural work focused mostly on DENV2, and therefore the other serotypes that are equally important are not well studied. In this research, we found that DENV3 can dramatically transform itself from a smooth, round particle to a club-shaped particle like golf clubs, which would help the virus to evade hosts' immune response, vaccines and therapeutics."
The research team also found some strains capable of transforming into club-shaped particles in DENV1, DENV2 and zika, though these exist as a minority of the virus population. Nonetheless, this suggests that flaviviruses have the potential to turn themselves into a conformation that is vastly different from their original structure, which can make vaccines and therapeutics ineffective against them.
Prof Dr Patrick Casey, Senior Vice Dean for Research at Duke-NUS commented,
"While Singapore has seen a recent spike in dengue cases, annually this virus infects about 400 million people worldwide, with a high prevalence in tropical and sub-tropical regions. In line with Duke-NUS vision of transforming medicine, this study gives new direction to developing better therapies and vaccines to treat or prevent dengue infections, and contribute to public health outcomes."
The research team is presently studying more DENV3 clinical strains to determine if this structural transformation is common.
For the latest Singapore Medical News, keep on logging to Thailand Medical News.


Source: COVID-19 Blood Clots
May 20, 2020  2 months ago
Source : Thailand Medical news
Feb 05, 2020  5 months ago